Transcript: Which HIV Meds Cause Lipoatrophy?

Transcript: Beyond Condoms: Medical Approaches For Prevention

Transcript: Simple Test Eliminates Abacavir Risk

Transcript: Are We Starting Treatment Early Enough?

Transcript: The Latest on Lipo: Advances & Setbacks

Prezista Superior to Kaletra for Treatment-Experienced Patients
Preliminary results from a major clinical trial have demonstrated that Prezista plus Norvir is more effective than Kaletra in treatment-experienced HIV-positive patients.

NNRTI Etravirine Effective for Treatment-Experienced Patients
Studies reviewed at the fourth IAS Conference in Sydney indicate that Tibotec's NNRTI etravirine, combined with the company's PI Prezista, is safe and effective for treatment-experienced HIV-positive patients.

PRO 140 Shows Promise in Single-Dose Study
Researchers have reported encouraging results from an early study of PRO 140, an experimental HIV entry inhibitor.

Tommy Morrison’s In-Ring Return Worries Boxing Officials

Connecticut Hospitals Offer Free HIV Testing in ERs

Cell Phone Soap Opera Helps Fight HIV

Not Enough Antibodies to Protect Against Superinfection
Most people’s immune response to HIV isn’t strong enough to protect them from being infected with a second strain of the virus, according to a study published in the December 2008 issue of the Journal of Virology and reported by ScienceDaily.

Up Kaletra Dose During Late Pregnancy
HIV-positive pregnant women should take a higher-than-normal dose of Kaletra (lopinavir/ritonavir) during the three months leading up to delivery, according to a study published online in the Journal of Acquired Immune Deficiency Syndromes (JAIDS). 

Circumcision Prevents HIV Infection in U.S. Heterosexual Men
Heterosexual African-American men who have been circumcised are less likely than non-circumcised men to become infected after being exposed to HIV, according to a U.S. study published in the January 1 issue of the Journal of Infectious Diseases and reported by ScienceDaily.

Generic Zerit Approved in United States
Three generic formulations of stavudine—originally marketed by Bristol-Myers Squibb (BMS) using the brand name Zerit—have been approved by the U.S. Food and Drug Administration (FDA) for use in both developing nations and the United States, according to an FDA announcement.

Does Smoking Reduce Kaposi’s Sarcoma Risk?
HIV-positive cigarette smokers may face a higher risk of cardiovascular disease, chronic obstructive pulmonary disease and various cancers, but they may also have a lower risk of Kaposi’s sarcoma (KS), according to a letter published by National Cancer Institute (NCI) researchers in the January 14 issue of AIDS.

A Test to Predict Responses to Hep C Treatment?
Current treatments for chronic hepatitis C virus (HCV) infection have severe side effects and fail in about half of treated patients, including people living with HIV. However, according to a ScienceDaily report, researchers at Saint Louis University have developed an approach that may predict the outcome of therapy, raising the possibility of a test to predict whether treatment will be effective before it is started.

Looking Back, Moving Forward: The Year in Treatment News
Now more than 25 years since the 1983 discovery of HIV as the cause of AIDS, research continues at a steady clip in pursuit of sound prevention strategies, better treatments and—with a little bit of luck—a cure. While 2008 wasn’t exactly a year of earth-shattering discoveries, there were advances, setbacks and a few telltale hints of interesting things to come in 2009. Here we review the top 10 treatment research developments that made us sit up straight during the past 12 months.